Grossman Adam S's Form 4 filing
Adma Biologics, Inc.ADMA · filed Jun 14, 2024
- Accession no.
- 0001140361-24-030232
- Filed
- Jun 14, 2024
- Trade date
- Jun 14, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.07M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grossman Adam SCIK 0001542517 | Director, Officer (President,CEO, and Interim CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock | JOtherDisposed | −460,000 | $3.21F2 | −$1,476,600 | 2,191,475 | Direct | |
| Jun 14, 2024 | Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 2,181,475 | Direct | |
| Jun 14, 2024 | Common Stock | SSaleDisposed | −100,000 | $10.72 | −$1,072,000 | 2,081,475 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.